Patents Assigned to Julius-Maximilians-Universitat Wurzburg
-
Publication number: 20210137407Abstract: A system for generating a traveling field free line, traveling along a propagation direction different from the orientation of said traveling field free line, said system comprising at least a first and a second coil assembly, wherein said first coil assembly is configured for generating a first stationary field free line at a first location when a current is flowing in the first coil assembly and the second coil assembly is current free, and wherein said second coil assembly is configured for generating a second stationary field free line at a second location, when a current is flowing in the second coil assembly and the first coil assembly is current free. The system further comprises a controller configured for driving the first and second coil assemblies with corresponding driving currents synchronized with each other, such that said traveling field free line travels along the propagation direction from a first location towards a second location.Type: ApplicationFiled: February 28, 2019Publication date: May 13, 2021Applicant: Julius-Maximilians-Universität Würzburg Servicezentrum Forschung und Technologietransfer Patente undInventors: Patrick VOGEL, Martin RÜCKERT, Volker Christian BEHR
-
Publication number: 20210113603Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.Type: ApplicationFiled: September 1, 2020Publication date: April 22, 2021Applicant: Julius-Maximilians-Universitat WurzburgInventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
-
Patent number: 10781251Abstract: The present invention relates to novel monoclonal anti-human-GDF-15 antibodies, pharmaceutical compositions, kits, methods and uses and the cell lines capable of producing the monoclonal antibodies described herein. The present invention further relates to novel antibodies to human GDF-15 capable of inhibiting cancer growth.Type: GrantFiled: March 12, 2018Date of Patent: September 22, 2020Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Jörg Wischhusen, Markus Junker, Thomas Müller, Stefan Saremba
-
Patent number: 10604565Abstract: The present invention relates to monoclonal anti-human-GDF-15 antibodies. The antibodies include chimeric antibodies and humanized antibodies. The invention also relates to monoclonal anti-human-GDF-15 antibodies including murine antibodies, chimeric antibodies and humanized antibodies for use in methods for the treatment of cancer cachexia and also for the treatment of cancer. The invention also provides pharmaceutical compositions, kits, methods and uses and cell lines capable of producing the monoclonal antibodies of the invention.Type: GrantFiled: March 5, 2018Date of Patent: March 31, 2020Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Jörg Wischhusen, Markus Junker, Tina Schäfer, Dirk Pühringer
-
Publication number: 20200069720Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.Type: ApplicationFiled: August 16, 2019Publication date: March 5, 2020Applicant: Julius-Maximilians-Universitat WurzburgInventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
-
Publication number: 20190345443Abstract: The present invention relates to a method for the culturing of cells on a cell culture substrate, wherein the cell culture substrate comprises a cell culture substrate made of glass and at least a part of the cell culture substrate made of glass has a surface with a nanoporous structure with an average pore diameter of 2 to 150 nm, and the use of a cell culture substrate for the culturing or differentiation of cells, as bottom of a cell culture vessel or bioreactor, as removable insert for cell culture vessels or bioreactors and/or as perfusive membrane for 3D cell culture reactors, whereby the cell culture substrate comprises a cell culture substrate made of glass and at least a part of the cell culture substrate made of glass has a surface with a nanoporous structure with an average pore diameter of 2 to 150 nm.Type: ApplicationFiled: April 23, 2019Publication date: November 14, 2019Applicants: FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG E.V., JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURGInventors: Martin EMMERT, Ferdinand SOMOROWSKY, Doris HEINRICH
-
Patent number: 10434117Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.Type: GrantFiled: June 22, 2018Date of Patent: October 8, 2019Assignee: Julius-Maximilians-Universitat WurzburgInventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
-
Publication number: 20190284296Abstract: The present invention relates to a set of polypeptides and its uses. In particular, the present invention relates to a set of polypeptides whereby this set comprises two polypeptides each of which comprises a targeting moiety “T” binding to an antigen “?” and a fragment of “F” of a functional domain, wherein said two polypeptides are not associated with each other in absence of a substrate that has “A” at (on) its surface and wherein, upon dimerization of “F”, the resulting dimer becomes functional. Furthermore, medical and diagnostic uses of said set are described. Moreover, the present invention relates to nucleic acid molecule(s) encoding said set of polypeptides. The present invention also relates to a vector comprising the nucleotide sequence of nucleic acid molecule(s) encoding said set of polypeptides. Furthermore, the present invention relates to pharmaceutical compositions comprising said set of polypeptides. Moreover, the present invention relates to a kit comprising said set of polypeptides.Type: ApplicationFiled: March 1, 2019Publication date: September 19, 2019Applicant: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventor: Gernot STUHLER
-
Patent number: 10261095Abstract: The present invention relates to the biomarkers for predicting the clinical response to anti-LPS immunoglobulin treatments in patients in need thereof. In particular, the invention provides methods for predicting the clinical response to an anti-LPS immunoglobulin treatment in a patient in need thereof, said method comprising the steps of evaluating the expression of a predictive biomarker selected from the group consisting of CD14, CD68, TLR4, TLR7, IL6, IL8, IL10, IFN-alpha, IGF1, CXCL1, CXCL9, CXCL10, RAGE, GDNF, BCHE, and combination thereof, in said patient.Type: GrantFiled: April 14, 2016Date of Patent: April 16, 2019Assignees: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG, IGNOVA GMBHInventors: Günter Sprotte, Ana Maria Waaga-Gasser
-
Patent number: 10253294Abstract: The present invention relates to a method for producing dendritic cells with increased capability to activate T cells, to dendritic cells obtainable by such a method, and to a pharmaceutical composition comprising such dendritic cells.Type: GrantFiled: December 18, 2014Date of Patent: April 9, 2019Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Marion Heuer, Manfred Lutz, Andreas Beilhack
-
Publication number: 20180360866Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.Type: ApplicationFiled: June 22, 2018Publication date: December 20, 2018Applicant: Julius-Maximilians-Universitat WurzburgInventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
-
Patent number: 10105414Abstract: The present invention relates to a pharmaceutical composition comprising a (poly)peptide which comprises or consists of QEP or a QEP derivative thereof a nucleic acid molecule encoding said (poly)peptide or a vector comprising said nucleic acid molecule, for use in the prevention or in the treatment of a disease or disorder caused by, physiologically linked to or associated with glucose and/or galactose uptake, wherein said pharmaceutical composition is to be administered under a high-sugar condition. Furthermore, the pharmaceutical composition of the invention is for use in increasing insulin sensitivity. The invention further relates to a food composition comprising said (poly)peptide. The invention further relates to a method of screening for and/or identifying a compound suitable to prevent or treat said disease or disorder under a high-sugar condition.Type: GrantFiled: April 23, 2015Date of Patent: October 23, 2018Assignee: Julius-Maximilians-Universität WürzburgInventors: Alexandra Friedrich, Jürgen Groll, Hermann Koepsell, Maike Veyhl-Wichmann
-
Patent number: 10028974Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.Type: GrantFiled: April 19, 2017Date of Patent: July 24, 2018Assignee: Julius-Maximilians-Universitat WurzburgInventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
-
Publication number: 20180080943Abstract: The present invention relates to the biomarkers for predicting the clinical response to anti-LPS immunoglobulin treatments in patients in need thereof. In particular, the invention provides methods for predicting the clinical response to an anti-LPS immunoglobulin treatment in a patient in need thereof, said method comprising the steps of evaluating the expression of a predictive biomarker selected from the group consisting of CD14, CD68, TLR4, TLR7, IL6, IL8, IL10, IFN-alpha, IGF1, CXCL1, CXCL9, CXCL10, RAGE, GDNF, BCHE, and combination thereof, in said patient.Type: ApplicationFiled: April 14, 2016Publication date: March 22, 2018Applicants: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURG, IGNOVA GMBHInventors: Günter SPROTTE, Ana Maria WAAGA-GASSER
-
Patent number: 9869674Abstract: The invention relates to a method for determining the presence of an analyte by means of a distribution of small magnetic particles. According to said method, the magnetizations of the small particles are oriented in relation to each other by means of an outer magnetic focusing field; once the focussing field has been terminated, the magnetizations of the small particles are rotated asynchronously to the magnetic field by means of an outer magnetic field of suitable field intensity and rotational frequency, which rotates about a longitudinal axis (z); the temporal course of the superpositioned transverse magnetization of the set of particles is detected; and the presence of the analyte is deduced from the detected temporal course. The invention also relates to a corresponding device (1).Type: GrantFiled: April 1, 2011Date of Patent: January 16, 2018Assignees: Hochschule für angewandte Wissenschaften Fachhochschule Würzburg-Schweinfurt, Julius-Maximilians-Universität-WürzburgInventors: Martin Rueckert, Volker C. Behr, Thomas Kampf
-
Patent number: 9814789Abstract: A radiopharmaceutical composition is disclosed comprising novel iodometomidate derivatives of formula (I) which bind specifically to adrenal enzymes and which exhibit an improved stability. The compounds of formula (I) are suitable for use in a diagnostic imaging method, e.g. for diagnosis of adrenocortical carcinoma. The compounds of formula (I) are further suitable for use in the treatment of adrenocortical carcinoma, by means of radionuclide therapy.Type: GrantFiled: September 26, 2013Date of Patent: November 14, 2017Assignee: Julius-Maximilians-Universität WürzburgInventors: Bruno Allolio, Andreas Schirbel, Stefanie Hahner
-
Publication number: 20170304347Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.Type: ApplicationFiled: April 19, 2017Publication date: October 26, 2017Applicant: Julius-Maximilians-Universitat WurzburgInventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross
-
Patent number: 9422365Abstract: The invention concerns a peptide or arrangement of peptides forming a Staphylococcus aureus epitope binding site comprising a first amino acid sequence and a second amino acid sequence, wherein the first amino acid sequence is at least 88% identical to sequence SEQ ID NO:1 and wherein the second amino acid sequence is at least 88% identical to sequence SEQ ID NO: 2.Type: GrantFiled: September 21, 2012Date of Patent: August 23, 2016Assignee: JULIUS-MAXIMILIANS-UNIVERSITÄT WÜRZBURGInventors: Knut Ohlsen, Udo Lorenz, Roland E. Kontermann
-
Patent number: 9383363Abstract: The invention relates to the use of LASP-1 in a urine sample obtained from a subject for diagnosing and/or grading transitional cell carcinoma. The invention furthermore relates to a method for diagnosing transitional cell carcinoma comprising detecting the presence or absence of LASP-1 in a urine sample obtained from a subject, wherein the presence of LASP-1 above 1 ng/500 ?l urine is indicative for transitional cell carcinoma and a method for grading transitional cell carcinoma comprising determining the level of LASP-1 in a urine sample obtained from a subject, wherein the level of LASP-1 correlates with the grade of the transitional cell carcinoma.Type: GrantFiled: December 6, 2012Date of Patent: July 5, 2016Assignee: Julius-Maximilians-Universität-WürzburgInventor: Elke Butt
-
Patent number: 9220722Abstract: In some embodiments, the invention is directed to a method for diagnosing fibrosis and/or fibrosis related diseases and to a method for screening a pharmaceutically active compound for the treatment of fibrosis and/or fibrosis related diseases. The present invention further relates to compositions for use in the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions modulate the activity of a miRNA for the treatment, amelioration, and/or prevention of fibrosis. In certain embodiments, the compositions inhibit the activity of miR-21 for the treatment, amelioration, and/or prevention of fibrosis.Type: GrantFiled: October 23, 2013Date of Patent: December 29, 2015Assignee: JULIUS-MAXIMILIANS-UNIVERSITAT WURZBURGInventors: Thomas Thum, Johann Bauersachs, Stefan Engelhardt, Carina Gross